Barclays lowered the firm’s price target on Avantor (AVTR) to $7 from $8.50 and keeps an Underweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Avantor adds advanced microbial, stability testing at St. Louis site
- Avantor price target lowered to $8.50 from $10 at Evercore ISI
- ESAB says R. Brent Jones to succeed Kevin Johnson as CFO
- Avantor Announces CFO Resignation and Interim Finance Leadership
- Avantor says CFO R. Brent Jones to leave company on, before June 24